These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11981148)

  • 21. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
    Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
    Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategy for Cardiovascular Surgery in Patients with Antithrombin III Deficiency.
    Nishimura Y; Takagi Y
    Ann Thorac Cardiovasc Surg; 2018 Aug; 24(4):187-192. PubMed ID: 29681597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass?
    Brinks HJ; Weerwind PW; Bogdan S; Verbruggen H; Brouwer MH
    Perfusion; 2001 Jan; 16(1):3-12. PubMed ID: 11192305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of antithrombin III in the perioperative management of the patient with unstable angina.
    Rossi M; Martinelli L; Storti S; Corrado M; Marra R; Varano C; Schiavello R
    Ann Thorac Surg; 1999 Dec; 68(6):2231-6. PubMed ID: 10617008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroperative effects of fresh frozen plasma and antithrombin III on heparin sensitivity and coagulation during nitroglycerine infusion in coronary artery bypass surgery.
    Kanbak M; Oc B; Salman MA; Ocal T; Oc M
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):593-9. PubMed ID: 21799398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass.
    Avidan MS; Levy JH; Scholz J; Delphin E; Rosseel PM; Howie MB; Gratz I; Bush CR; Skubas N; Aldea GS; Licina M; Bonfiglio LJ; Kajdasz DK; Ott E; Despotis GJ
    Anesthesiology; 2005 Feb; 102(2):276-84. PubMed ID: 15681940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the neutrophil elastase inhibitor sivelestat on perioperative inflammatory response after pediatric heart surgery with cardiopulmonary bypass: a prospective randomized study.
    Kohira S; Oka N; Inoue N; Itatani K; Hanayama N; Kitamura T; Fujii M; Takeda A; Oshima H; Tojo K; Yoshitake S; Miyaji K
    Artif Organs; 2013 Dec; 37(12):1027-33. PubMed ID: 23834653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.
    Nakahira A; Sasaki Y; Hirai H; Fukui T; Matsuo M; Takahashi Y; Kotani S; Suehiro S
    Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):555-60. PubMed ID: 20061337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technology evaluation: transgenic antithrombin III (rhAT-III), Genzyme Transgenics.
    Yeung PK
    Curr Opin Mol Ther; 2000 Jun; 2(3):336-9. PubMed ID: 11249629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel blood-sparing agent in cardiac surgery? First in-patient experience with the synthetic serine protease inhibitor MDCO-2010: a phase II, randomized, double-blind, placebo-controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.
    Englberger L; Dietrich W; Eberle B; Erdoes G; Keller D; Carrel T
    Anesth Analg; 2014 Jul; 119(1):16-25. PubMed ID: 24722261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gabexate mesilate and antithrombin III for intraoperative anticoagulation in heparin pretreated patients.
    Ranucci M; Cazzaniga A; Isgrò G; Ditta A; Boncilli A; Cotza M; Brozzi S
    Perfusion; 1999 Sep; 14(5):357-62. PubMed ID: 10499652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
    Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
    Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of antithrombin III (AT III) substitution to supranormal activities on systemic procoagulant turnover in patients with end-stage chronic liver disease.
    Scherer R; Kabatnik M; Erhard J; Peters J
    Intensive Care Med; 1997 Nov; 23(11):1150-8. PubMed ID: 9434921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial experience with recombinant antithrombin to treat antithrombin deficiency in patients on extracorporeal membrane oxygenation.
    Niimi KS; Fanning JJ
    J Extra Corpor Technol; 2014 Mar; 46(1):84-90. PubMed ID: 24779124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of ulinastatin on coagulation and platelet function in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass].
    Ji HW; Chen L
    Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(3):175-8. PubMed ID: 19537033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ; Ofosu FA; Buchanan MR
    Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update.
    Rodgers GM
    Thromb Haemost; 2009 May; 101(5):806-12. PubMed ID: 19404531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.